CHAL 38 |
| The expectations of and approach by a large pharmaceutical company in a collaboration differ dramatically from those of its smaller licensor. A discussion of the challenges relating to one such collaboration will be used to illustrate the kinds of important issues that arise and which of them can and cannot be addressed by the collaboration agreement itself. |
|
Paradise Lost: Intellectual Property Protection for Pharmaceuticals
12:00 PM-2:50 PM, Wednesday, August 22, 2007 BCEC -- 257B, Oral
Division of Chemistry & the Law |